Perioperative immunotherapy for esophageal squamous cell carcinoma

被引：6

作者：

Wei, Dan D. ^{[1
,2
,3
]}

Fang, Jin M. ^{[1
,3
]}

Wang, Huan Z. ^{[1
]}

Chen, Jian ^{[2
]}

Kong, Shuai ^{[2
,3
]}

Jiang, Yan-Yi ^{[2
,3
]}

Jiang, Yuan ^{[2
,3
]}

机构：

[1] Hefei Canc Hosp, Chinese Acad Sci, Esophageal & Gastrointestinal Tumor Ctr, Hefei, Peoples R China

[2] Chinese Acad Sci, Inst Hlth & Med Technol, Hefei Inst Phys Sci, Anhui Prov Key Lab Med Phys & Technol, Hefei, Peoples R China

[3] Univ Sci & Technol China, Sci Isl Branch, Grad Sch, Hefei, Peoples R China

来源：

FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷

基金：

中国国家自然科学基金;

关键词：

esophageal squamous cell carcinoma; immunotherapy; chemotherapy; immune checkpoint blockade; PD1/PD-L1; PEMBROLIZUMAB PLUS CHEMOTHERAPY; METASTATIC NONSQUAMOUS NSCLC; 1ST-LINE TREATMENT; OPEN-LABEL; DOUBLE-BLIND; MOLECULAR CHARACTERIZATION; HEPATOCELLULAR-CARCINOMA; 2ND-LINE THERAPY; SINGLE-ARM; CANCER;

D O I：

10.3389/fimmu.2024.1330785

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Esophageal squamous cell carcinoma (ESCC) is the main prevalent histological subtype and accounts for 85% of esophageal cancer cases worldwide. Traditional treatment for ESCC involves chemotherapy, radiotherapy, and surgery. However, the overall prognosis remains unfavorable. Recently, immune checkpoint blockade (ICB) therapy using anti-programmed cell death-1 (PD-1)/PD-1 ligand (PD-L1) antibodies have not only achieved remarkable benefits in the clinical management of ESCC but have also completely changed the treatment approach for this cancer. In just a few years, ICB therapy has rapidly advanced and been added to standard first-line treatment regimen in patients with ESCC. However, preoperative immunotherapy is yet to be approved. In this review, we summarize the ICB antibodies commonly used in clinical immunotherapy of ESCC, and discuss the advances of immunotherapy combined with chemotherapy and radiotherapy in the perioperative treatment of ESCC, aiming to provide reference for clinical management of ESCC patients across the whole course of treatment.

引用

页数：9

共 75 条

[1] First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial [J].

Baas, Paul ;

Scherpereel, Arnaud ;

Nowak, Anna K. ;

Fujimoto, Nobukazu ;

Peters, Solange ;

Tsao, Anne S. ;

Mansfield, Aaron S. ;

Popat, Sanjay ;

Jahan, Thierry ;

Antonia, Scott ;

Oulkhouir, Youssef ;

Bautista, Yolanda ;

Cornelissen, Robin ;

Greillier, Laurent ;

Grossi, Francesco ;

Kowalski, Dariusz ;

Rodriguez-Cid, Jeronimo ;

Aanur, Praveen ;

Oukessou, Abderrahim ;

Baudelet, Christine ;

Zalcman, Gerard .

LANCET, 2021, 397 (10272) :375-386

[2] Uncovering the complex role of interferon-gamma in suppressing type 2 immunity to cancer [J].

Bhat, Asif Ahmad ;

Goyal, Ahsas ;

Thapa, Riya ;

Almalki, Waleed Hassan ;

Kazmi, Imran ;

Alzarea, Sami I. ;

Singh, Mahaveer ;

Rohilla, Suman ;

Saini, Tarun Kumar ;

Kukreti, Neelima ;

Meenakshi, Dhanalekshmi Unnikrishnan ;

Fuloria, Neeraj Kumar ;

Sekar, Mahendran ;

Gupta, Gaurav .

CYTOKINE, 2023, 171

[3] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [J].

Burtness, Barbara ;

Harrington, Kevin J. ;

Greil, Richard ;

Soulieres, Denis ;

Tahara, Makoto ;

de Castro, Gilberto, Jr. ;

Psyrri, Amanda ;

Baste, Neus ;

Neupane, Prakash ;

Bratland, Ase ;

Fuereder, Thorsten ;

Hughes, Brett G. M. ;

Mesia, Ricard ;

Ngamphaiboon, Nuttapong ;

Rordorf, Tamara ;

Ishak, Wan Zamaniah Wan ;

Hong, Ruey-Long ;

Mendoza, Rene Gonzalez ;

Roy, Ananya ;

Zhang, Yayan ;

Gumuscu, Burak ;

Cheng, Jonathan D. ;

Jin, Fan ;

Rischin, Danny .

LANCET, 2019, 394 (10212) :1915-1928

[4]

Cai LT, 2023, J HEMATOL ONCOL, V16, DOI 10.1186/s13045-023-01499-1

[5] Patterns and trends in esophageal cancer incidence and mortality in China: An analysis based on cancer registry data [J].

Chen, Ru ;

Zheng, Rongshou ;

Zhang, Siwei ;

Wang, Shaoming ;

Sun, Kexin ;

Zeng, Hongmei ;

Li, Li ;

Wei, Wenqiang ;

He, Jie .

JOURNAL OF THE NATIONAL CANCER CENTER, 2023, 3 (02) :21-27

[6] Risk Prediction Model for Esophageal Cancer Among General Population: A Systematic Review [J].

Chen, Ru ;

Zheng, Rongshou ;

Zhou, Jiachen ;

Li, Minjuan ;

Shao, Dantong ;

Li, Xinqing ;

Wang, Shengfeng ;

Wei, Wenqiang .

FRONTIERS IN PUBLIC HEALTH, 2021, 9

[7] Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial [J].

Chen, Xiaofeng ;

Xu, Xiang ;

Wang, Danping ;

Liu, Jinyuan ;

Sun, Jing ;

Lu, Mingjie ;

Wang, Rui ;

Hui, Bingqing ;

Li, Xiaofei ;

Zhou, Chenchen ;

Wang, Min ;

Qiu, Tianzhu ;

Cui, Shiyun ;

Sun, Nana ;

Li, Yang ;

Wang, Fufeng ;

Liu, Cuicui ;

Shao, Yang ;

Luo, Jinhua ;

Gu, Yanhong .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (02)

[8]

Cheng Y, 2023, J THORAC ONCOL, V18, pS46

[9]

Cortes J, 2020, LANCET, V396, P1817, DOI 10.1016/S0140-6736(20)32531-9

[10] Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study [J].

Diaz, Luis A. ;

Shiu, Kai-Keen ;

Kim, Tae-Won ;

Jensen, Benny Vittrup ;

Jensen, Lars Henrik ;

Punt, Cornelis ;

Smith, Denis ;

Garcia-Carbonero, Rocio ;

Benavides, Manuel ;

Gibbs, Peter ;

de la Fourchardiere, Christelle ;

Rivera, Fernando ;

Elez, Elena ;

Le, Dung T. ;

Yoshino, Takayuki ;

Zhong, Wen Yan ;

Fogelman, David ;

Marinello, Patricia ;

Andre, Thierry .

LANCET ONCOLOGY, 2022, 23 (05) :659-670

← 1 2 3 4 5 6 7 8 →